NCT07460856Recruiting
Effects of Cranberry on Gut and Metabolic Health
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
The consumption of plant-based foods, particularly berries, has been associated with improved health due to their high content of bioactive compounds. Among these, polyphenols-especially proanthocyanidins (PACs)-may offer protective effects against chronic diseases related to overweight and obesity. Cranberries are naturally rich in PACs and may positively influence metabolic health by modulating the gut microbiota. However, their specific effects on intestinal integrity and broader metabolic outcomes remain underexplored. The primary aim of this study is to assess the effects of cranberry supplementation on glucose metabolism, insulin sensitivity, blood lipid levels, and the composition and function of the gut microbiota in overweight and obese individuals. This randomized, double-blind, placebo-controlled, crossover clinical trial will include two 12-week intervention periods-one with a cranberry beverage and one with a placebo-separated by a 4-week washout period and preceded by a 2-week lifestyle stabilization phase. Participants will undergo comprehensive metabolic assessments (glucose control, insulin sensitivity, lipid profile), body composition analysis, gut microbiota profiling, and liver fat imaging (MRI in a subsample of female participants). Additional evaluations will include markers of inflammation, appetite regulation, intestinal health, and lifestyle factors.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 73 (estimated)
- First submitted
- 28 Jan 2026
- Start date
- 7 Jul 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Laval University
- Diseases
- Obesity
- NCT number
- NCT07460856
What you commit to
- Study type: Interventional
- Planned participants: 73
- From 7 Jul 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- taking medication which may affect the study outcomes (i.e. antidiabetic and/or cholesterol or lipid-lowering medications and/or glucocorticosteroid in supraphysiological doses and/or anti-obesity medications)
- had undergone major surgery 3 months prior to the study or if they had one planned
Other illness
- having a significant change in body weight in the past 3 months (±5% of their body weight) due to bariatric surgery or other conditions
- having eating disorders
- if they had intestinal malabsorption, cirrhosis or chronic kidney disease
Other
- to have aversion to cranberry products
- regularly drinking alcohol (\>2 glasses/day)
- taking regular probiotics and prebiotics (including fruit/berry polyphenol supplements) in the past 3 months
- being pregnant, planning a pregnancy, or breastfeeding.
Who the study is looking for
- body mass index between 25 and 40 kg/m2
- at least one of the following criteria: fasting plasma insulin \>60 pmol/L, fasting glycemia between 5.5 and 6.9 mmol/L, glycated hemoglobin (HbA1c) level of 5.7- 6.4% and/or fasting triglyceride \>1.35 mmol/L.
Age in the registry: 25 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| INAF, Université Laval Coordinator of this site? Confirm its status | Québec | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.